A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s ...

CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound ...

CVS Caremark was sued Wednesday by two health plan participants who say the pharmacy benefit manager wrongly refuses to cover ...

ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective ...

Benefits consultants Aon and WTW told the Wall Street Journal that employer health-coverage costs are set to surge about 9.5% ...

Two New York residents have filed a lawsuit against CVS after the company’s pharmacy benefit manager, Caremark, denied coverage for Zepbound in favor of Wegovy. The plaintiffs — Dennis Larkin of ...